2025 Q3 -tulosraportti
50 päivää sitten52 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2 246
Myynti
Määrä
1 694
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 180 | - | - | ||
| 398 | - | - | ||
| 226 | - | - | ||
| 34 | - | - | ||
| 13 | - | - |
Ylin
10,84VWAP
Alin
10,54VaihtoMäärä
0,6 57 765
VWAP
Ylin
10,84Alin
10,54VaihtoMäärä
0,6 57 765
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 24.10. | |
| 2025 Q2 -tulosraportti | 18.7. | |
| 2025 Q1 -tulosraportti | 6.5. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·24.11.This year's flu unfortunately seems to be quite tough, but cynically enough, it's good for Sedana.
·8.12.Not a fan of sedating these patients with iso. Rather, as healthy patients as possible ironically can become their niche, but that proportion of patients in a random IVA is much smaller than the 20% market share they claim to want. Soon time for new bla around from my side because now the question is whether they even clear FDA without a New Issue?- ·24.10.I own some shares so I'm thinking about what I should do. Sales ex currency are admittedly somewhat disappointing, but seasonal variations can be quite large and they sold very well in Q2. If they sell for approximately 200 million this year and 220 million with a current gross margin of approximately 72%, then the company ex USA should be worth quite a lot - PS sales of approximately 5-6 times would be reasonable if one compares with other medtech companies. There isn't much talk about a deal in USA, but it's clear that they can choose to reconsider their strategy of selling themselves, which I really think they should because USA is almost impossible for a Swedish company to cover. Just finding good salespeople is almost impossible.
27.10.27.10.I think the price is low considering that the company is now really close to entering the US market and has also achieved more sustainable growth and expansion in Europe. Things are not happening as quickly in this industry as perhaps previously expected. Entering the US market would certainly generate interest from investors and boost the share price.
19.11.19.11.Propably a roller coaster ahead with the share price, but jumping off at this stage does not make sense - just prior to the commercial launch on the US market planned to early 2026, unless you are a short trader. - ·23.10.Placed a small short position for tomorrow's report 1) burning cash 2) product that is not a paradigm shift but at best a niche product that can take a small part (1-3%?) of the sedation market against the company's ambitious 20% (is that goal still valid btw?) 3) never seems to reach its goal. Is a new share issue (NE) imminent?·24.10.But don't you consider taking out a loan as an option, should liquidity be needed? There's probably no reason to scare with the risk of an issuance (I assume you mean a rights issue by that.)
·24.10.How can you borrow from a bank for a business with negative cash flows and a balance sheet that exclusively consists of intangible assets. In that case, they might have to issue a convertible with high interest perhaps… 
·26.9.Does a possible FDA approval, which Sedana has been fighting for for years, have any value now, when Trump is imposing tariffs of 100%?·26.9.Yes, of course. An FDA ALWAYS has value - even if one might subsequently choose not to sell in Trump country. But maybe not, it's already in the red on the financial side: 18 Jul. 09:57 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) Sedana Medical, active in inhalation sedation, is rising around 7 percent after the report for the second quarter was well received. The company's operating profit was -9.5 million SEK during the quarter, compared to -18 million SEK in the same period last year. Net sales amounted to 49.8 million SEK, compared to 41.1 million SEK in the corresponding quarter the previous year. In the report, the CEO's statement writes that the company's main market, Germany, showed 19 percent sales growth. In addition to Germany, Spain also showed strong results. The CEO's statement also touches on the US approval of an early access program (EAP), which Nyhetsbyrån Direkt wrote about on 23 April. "We have received a lot of interest from hospitals wanting to participate in our Expanded Access Program and expect the first patients to be treated in the second half of this year," writes Johannes Doll.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
50 päivää sitten52 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·24.11.This year's flu unfortunately seems to be quite tough, but cynically enough, it's good for Sedana.·8.12.Not a fan of sedating these patients with iso. Rather, as healthy patients as possible ironically can become their niche, but that proportion of patients in a random IVA is much smaller than the 20% market share they claim to want. Soon time for new bla around from my side because now the question is whether they even clear FDA without a New Issue?
- ·24.10.I own some shares so I'm thinking about what I should do. Sales ex currency are admittedly somewhat disappointing, but seasonal variations can be quite large and they sold very well in Q2. If they sell for approximately 200 million this year and 220 million with a current gross margin of approximately 72%, then the company ex USA should be worth quite a lot - PS sales of approximately 5-6 times would be reasonable if one compares with other medtech companies. There isn't much talk about a deal in USA, but it's clear that they can choose to reconsider their strategy of selling themselves, which I really think they should because USA is almost impossible for a Swedish company to cover. Just finding good salespeople is almost impossible.27.10.27.10.I think the price is low considering that the company is now really close to entering the US market and has also achieved more sustainable growth and expansion in Europe. Things are not happening as quickly in this industry as perhaps previously expected. Entering the US market would certainly generate interest from investors and boost the share price.19.11.19.11.Propably a roller coaster ahead with the share price, but jumping off at this stage does not make sense - just prior to the commercial launch on the US market planned to early 2026, unless you are a short trader.
- ·23.10.Placed a small short position for tomorrow's report 1) burning cash 2) product that is not a paradigm shift but at best a niche product that can take a small part (1-3%?) of the sedation market against the company's ambitious 20% (is that goal still valid btw?) 3) never seems to reach its goal. Is a new share issue (NE) imminent?·24.10.But don't you consider taking out a loan as an option, should liquidity be needed? There's probably no reason to scare with the risk of an issuance (I assume you mean a rights issue by that.)·24.10.How can you borrow from a bank for a business with negative cash flows and a balance sheet that exclusively consists of intangible assets. In that case, they might have to issue a convertible with high interest perhaps…
- ·26.9.Does a possible FDA approval, which Sedana has been fighting for for years, have any value now, when Trump is imposing tariffs of 100%?·26.9.Yes, of course. An FDA ALWAYS has value - even if one might subsequently choose not to sell in Trump country. But maybe not, it's already in the red on the financial side: 18 Jul. 09:57 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) Sedana Medical, active in inhalation sedation, is rising around 7 percent after the report for the second quarter was well received. The company's operating profit was -9.5 million SEK during the quarter, compared to -18 million SEK in the same period last year. Net sales amounted to 49.8 million SEK, compared to 41.1 million SEK in the corresponding quarter the previous year. In the report, the CEO's statement writes that the company's main market, Germany, showed 19 percent sales growth. In addition to Germany, Spain also showed strong results. The CEO's statement also touches on the US approval of an early access program (EAP), which Nyhetsbyrån Direkt wrote about on 23 April. "We have received a lot of interest from hospitals wanting to participate in our Expanded Access Program and expect the first patients to be treated in the second half of this year," writes Johannes Doll.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2 246
Myynti
Määrä
1 694
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 180 | - | - | ||
| 398 | - | - | ||
| 226 | - | - | ||
| 34 | - | - | ||
| 13 | - | - |
Ylin
10,84VWAP
Alin
10,54VaihtoMäärä
0,6 57 765
VWAP
Ylin
10,84Alin
10,54VaihtoMäärä
0,6 57 765
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 24.10. | |
| 2025 Q2 -tulosraportti | 18.7. | |
| 2025 Q1 -tulosraportti | 6.5. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
50 päivää sitten52 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 24.10. | |
| 2025 Q2 -tulosraportti | 18.7. | |
| 2025 Q1 -tulosraportti | 6.5. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 24.10.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·24.11.This year's flu unfortunately seems to be quite tough, but cynically enough, it's good for Sedana.·8.12.Not a fan of sedating these patients with iso. Rather, as healthy patients as possible ironically can become their niche, but that proportion of patients in a random IVA is much smaller than the 20% market share they claim to want. Soon time for new bla around from my side because now the question is whether they even clear FDA without a New Issue?
- ·24.10.I own some shares so I'm thinking about what I should do. Sales ex currency are admittedly somewhat disappointing, but seasonal variations can be quite large and they sold very well in Q2. If they sell for approximately 200 million this year and 220 million with a current gross margin of approximately 72%, then the company ex USA should be worth quite a lot - PS sales of approximately 5-6 times would be reasonable if one compares with other medtech companies. There isn't much talk about a deal in USA, but it's clear that they can choose to reconsider their strategy of selling themselves, which I really think they should because USA is almost impossible for a Swedish company to cover. Just finding good salespeople is almost impossible.27.10.27.10.I think the price is low considering that the company is now really close to entering the US market and has also achieved more sustainable growth and expansion in Europe. Things are not happening as quickly in this industry as perhaps previously expected. Entering the US market would certainly generate interest from investors and boost the share price.19.11.19.11.Propably a roller coaster ahead with the share price, but jumping off at this stage does not make sense - just prior to the commercial launch on the US market planned to early 2026, unless you are a short trader.
- ·23.10.Placed a small short position for tomorrow's report 1) burning cash 2) product that is not a paradigm shift but at best a niche product that can take a small part (1-3%?) of the sedation market against the company's ambitious 20% (is that goal still valid btw?) 3) never seems to reach its goal. Is a new share issue (NE) imminent?·24.10.But don't you consider taking out a loan as an option, should liquidity be needed? There's probably no reason to scare with the risk of an issuance (I assume you mean a rights issue by that.)·24.10.How can you borrow from a bank for a business with negative cash flows and a balance sheet that exclusively consists of intangible assets. In that case, they might have to issue a convertible with high interest perhaps…
- ·26.9.Does a possible FDA approval, which Sedana has been fighting for for years, have any value now, when Trump is imposing tariffs of 100%?·26.9.Yes, of course. An FDA ALWAYS has value - even if one might subsequently choose not to sell in Trump country. But maybe not, it's already in the red on the financial side: 18 Jul. 09:57 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) Sedana Medical, active in inhalation sedation, is rising around 7 percent after the report for the second quarter was well received. The company's operating profit was -9.5 million SEK during the quarter, compared to -18 million SEK in the same period last year. Net sales amounted to 49.8 million SEK, compared to 41.1 million SEK in the corresponding quarter the previous year. In the report, the CEO's statement writes that the company's main market, Germany, showed 19 percent sales growth. In addition to Germany, Spain also showed strong results. The CEO's statement also touches on the US approval of an early access program (EAP), which Nyhetsbyrån Direkt wrote about on 23 April. "We have received a lot of interest from hospitals wanting to participate in our Expanded Access Program and expect the first patients to be treated in the second half of this year," writes Johannes Doll.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
2 246
Myynti
Määrä
1 694
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 180 | - | - | ||
| 398 | - | - | ||
| 226 | - | - | ||
| 34 | - | - | ||
| 13 | - | - |
Ylin
10,84VWAP
Alin
10,54VaihtoMäärä
0,6 57 765
VWAP
Ylin
10,84Alin
10,54VaihtoMäärä
0,6 57 765
Välittäjätilasto
Dataa ei löytynyt